An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors.
IDE397-001
Phase 1 other active
Quick answer
An Open Label, Phase 1, Treatment Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of IDE397 (MAT2A Inhibitor) In Adult Participants with Advanced Solid Tumors. for Advanced Solid Tumors is a Phase 1 program (other) at IDEAYA Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- IDEAYA Biosciences
- Indication
- Advanced Solid Tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active